MX2021011610A - Combinaciones de iadademstat para terapia contra el cancer. - Google Patents
Combinaciones de iadademstat para terapia contra el cancer.Info
- Publication number
- MX2021011610A MX2021011610A MX2021011610A MX2021011610A MX2021011610A MX 2021011610 A MX2021011610 A MX 2021011610A MX 2021011610 A MX2021011610 A MX 2021011610A MX 2021011610 A MX2021011610 A MX 2021011610A MX 2021011610 A MX2021011610 A MX 2021011610A
- Authority
- MX
- Mexico
- Prior art keywords
- iadademstat
- combinations
- cancer therapy
- cancer
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a combinaciones, métodos y composiciones para el tratamiento del cáncer que comprenden la administración de iadademstat en combinación con un inhibidor de PD(L)1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19382206 | 2019-03-25 | ||
PCT/EP2020/058362 WO2020193631A1 (en) | 2019-03-25 | 2020-03-25 | Combinations of iadademstat for cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011610A true MX2021011610A (es) | 2021-10-13 |
Family
ID=66175363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011610A MX2021011610A (es) | 2019-03-25 | 2020-03-25 | Combinaciones de iadademstat para terapia contra el cancer. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220175698A1 (es) |
EP (1) | EP3946295A1 (es) |
JP (1) | JP2022526525A (es) |
KR (1) | KR20210142614A (es) |
CN (1) | CN113573702A (es) |
AU (1) | AU2020249493A1 (es) |
BR (1) | BR112021016171A2 (es) |
CA (1) | CA3132473A1 (es) |
IL (1) | IL286353A (es) |
MX (1) | MX2021011610A (es) |
SG (1) | SG11202109025XA (es) |
WO (1) | WO2020193631A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2849564C (en) | 2011-10-20 | 2020-10-20 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
US20190256929A1 (en) * | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
US11685782B2 (en) * | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
-
2020
- 2020-03-25 KR KR1020217028840A patent/KR20210142614A/ko unknown
- 2020-03-25 CA CA3132473A patent/CA3132473A1/en active Pending
- 2020-03-25 JP JP2021557187A patent/JP2022526525A/ja active Pending
- 2020-03-25 CN CN202080018266.2A patent/CN113573702A/zh active Pending
- 2020-03-25 AU AU2020249493A patent/AU2020249493A1/en active Pending
- 2020-03-25 US US17/441,758 patent/US20220175698A1/en active Pending
- 2020-03-25 BR BR112021016171-6A patent/BR112021016171A2/pt unknown
- 2020-03-25 MX MX2021011610A patent/MX2021011610A/es unknown
- 2020-03-25 WO PCT/EP2020/058362 patent/WO2020193631A1/en unknown
- 2020-03-25 SG SG11202109025XA patent/SG11202109025XA/en unknown
- 2020-03-25 EP EP20712594.9A patent/EP3946295A1/en active Pending
-
2021
- 2021-09-13 IL IL286353A patent/IL286353A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022526525A (ja) | 2022-05-25 |
AU2020249493A1 (en) | 2021-09-16 |
EP3946295A1 (en) | 2022-02-09 |
KR20210142614A (ko) | 2021-11-25 |
IL286353A (en) | 2021-10-31 |
US20220175698A1 (en) | 2022-06-09 |
CN113573702A (zh) | 2021-10-29 |
SG11202109025XA (en) | 2021-09-29 |
CA3132473A1 (en) | 2020-10-01 |
WO2020193631A1 (en) | 2020-10-01 |
BR112021016171A2 (pt) | 2021-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220070A (es) | Inhibidores de parp1 | |
MX2019001920A (es) | Arn la terapia contra el cancer. | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
SG10201902664RA (en) | Combination therapy for treating cancer | |
MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
MX2020001727A (es) | Terapia de combinacion. | |
PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
MX2022001004A (es) | Inhibidores de enzimas. | |
MX2019013862A (es) | Terapia de combinacion. | |
PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy | |
MX2020011817A (es) | Metodos para tratar el linfoma. | |
MY200161A (en) | Bacteria for targeting tumors and treating cancer | |
WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
MX2023001425A (es) | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. | |
PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
MX2022005250A (es) | Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. | |
MX2021011610A (es) | Combinaciones de iadademstat para terapia contra el cancer. |